### Claims

What is claimed is:

# 5 1. A compound of formula I:

or a pharmaceutically acceptable salt thereof wherein:

10 A is O,

NH, or

S;

B is

15  $C(=O)R_1$ ,

 $C(=S)R_1$ ,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

20 C(=O)-heteteroaryl;

D is N when E is C and F is CH when "----" is a bond, or D is CH when E is N and F is CH<sub>2</sub> when "-----" is absent;

25 P is

attachment; and

5

is 5-membered heterocyclo or heteroaryl, wherein " indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR5, OC(=O)R1, NR6R7, NR5, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one

or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>,

NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>;

15

10

J, K, Q independently are CR<sub>2</sub> or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR<sub>2</sub>;

X, Y, Z independently are  $C=C-R_5$ , O=C,

20

CHR<sub>3</sub>,

 $CH_2$ 

CHR<sub>4</sub>,

CR<sub>3</sub>R<sub>4</sub>,

CH(OR<sub>5</sub>), or

### CHNR<sub>6</sub>R<sub>7</sub>;

R<sub>1</sub> is H,  $(C_1-C_8)$ alkyl, 5 (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1-C_4)alkyl$ , O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1-C_4)$  alkyl, S-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 10 NH<sub>2</sub>,  $NH(C_1-C_4)alkyl,$  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 15 R<sub>2</sub> is H, halo,  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 20 S— $(C_1$ - $C_4)$  alkyl, S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)alkyl, 25  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; R<sub>3</sub> and R<sub>4</sub> independently are halo,  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 30 O— $(C_1$ - $C_4$ )alkyl,

O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

```
S—(C_1-C_4) alkyl,
                                           S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                            NH<sub>2</sub>,
                                            NH(C_1-C_4)alkyl,
 5
                                           N((C_1-C_4)alkyl)_2,
                                            NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;
                                            aryl,
                                            (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                            heterocyclo,
10
                                            (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
                                            heteroaryl, or
                                            (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                wherein n is 0, 1, 2, or 3;
15
                                R<sub>5</sub> is H,
                                            (C_1-C_8)alkyl,
                                            (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                            aryl,
                                            (CH_2)_n-aryl,
20
                                            heterocyclo,
                                            (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
                                            heteroaryl, or
                                            (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                wherein n is as defined above;
25
                                R<sub>6</sub> and R<sub>7</sub> independently are H,
                                            (C_1-C_8)alkyl,
                                            (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                            aryl,
30
                                            (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                            heterocyclo,
                                            (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
```

# heteroaryl, or

# $(CH_2)_n$ -heteroaryl;

wherein n is 0, 1, 2, or 3; or  $R_6$  and  $R_7$  together can form a 5-7-membered ring containing 1, 2, or 3 heteroatoms which are N or S.

5

2. The compound of claim 1, wherein is						
day June	S. S	N N R <sub>3</sub>	of the s	Average of the second	N.N. B.	3-N N
N.O.	N.S.	O'N	ON R3	S N R3	HN N R <sub>3</sub>	N=N
HN NH	O S R <sub>3</sub>	O O O R3	SN R <sub>3</sub>	R <sub>3</sub> -N N N R <sub>3</sub>	S	R <sub>3</sub> -N
R <sub>3</sub> -N	· O war	S	R <sub>3</sub> -N	O John	R <sub>3</sub> -N	, roc
SN	N N F	13-NN	ON=N	8 N=N	,	Jun
HN II N	ON R <sub>3</sub>	S N R <sub>3</sub>	HN N R3	√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√√		

3. The compound of claim 1 as designated in formula IA.

4. The compound of claim 1 as designated in formula IB.

The compound of claim 1 as designated in formula IC.

10

5

5.

6. The compound of claim 5, wherein P is

7. The compound of claim 6, wherein P is

5

10

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F, and wherein " $\infty$ " indicates the point of attachment.

8. The compound of claim 7, wherein P is

wherein " " indicates the point of attachment; and wherein  $R_8$  and  $R_9$  are each independently H;halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl, O— $(C_1-C_4)$  alkyl, S— $(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl; wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form C=O.

## 9. A compound of formula II

5

10

15

or a pharmaceutically acceptable salt thereof wherein

NH, or S; 
$$B \text{ is} \\ C(=0)R_1, \\ C(=S)R_1,$$

A is O,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

5

10

15

20

25

D is N when E is C and F is CH when "-----" is a bond, or D is CH when E is N and F is CH<sub>2</sub> when "-----" is absent;

V÷w het

is 5-membered heterocyclo or heteroaryl, wherein "indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>, NHC=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>;

J, K, Q independently are  $CR_2$  or N, with the proviso that when any one of J, K, or Q is N, then the other two are  $CR_2$ ;

X, Y, Z independently are C=C - R<sub>5</sub>, O=C,

 $CH_2$ 

CHR<sub>3</sub>,

CHR<sub>4</sub>,

CR<sub>3</sub>R<sub>4</sub>

 $CH(OR_5)$ , or

CHNR<sub>6</sub>R<sub>7</sub>;

30

R<sub>1</sub> is H,

 $(C_1-C_8)$ alkyl,

(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 5 S— $(C_1$ - $C_4)$  alkyl, S— $(C_3$ - $C_6)$ cycloalkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 10 R<sub>2</sub> is H, halo,  $(C_1-C_8)$ alkyl, 15 (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1$ - $C_4)$  alkyl, S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 20  $NH_2$ ,  $NH(C_1-C_4)alkyl$ ,  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; R<sub>3</sub> and R<sub>4</sub> independently are H, halo, 25  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1$ - $C_4)$  alkyl, 30 S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, NH<sub>2</sub>,

```
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,
                                         N((C_1-C_4)alkyl)_2,
                                         NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;
                                          aryl,
5
                                          (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                         heterocyclo,
                                          (CH_2)_n-heterocyclo,
                                          heteroaryl, or
                                          (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
10
                              wherein n is 0, 1, 2, or 3;
                              R<sub>5</sub> is H,
                                          (C_1-C_8)alkyl,
                                          (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
15
                                          aryl,
                                          (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                          heterocyclo,
                                          (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
                                          heteroaryl, or
20
                                          (CH_2)_n-heteroaryl;
                               wherein n is 0, 1, 2, or 3;
                              R<sub>6</sub> and R<sub>7</sub> independently are H;
                                          (C_1-C_8)alkyl,
                                          (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
25
                                          aryl,
                                          (CH_2)_n-aryl,
                                          heterocyclo,
                                          (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
30
                                          heteroaryl, or
                                          (CH_2)_n-heteroaryl;
```

wherein n is 0, 1, 2, or 3; or  $R_6$  and  $R_7$  together can form a 5-7-membered ring containing 1, 2, or 3 heteroatoms which are N or S.

- 10. The compound of claim 9, wherein is as defined in claim 2.
- 11. The compound of claim 9as designated in formula IIA.

10 12. The compound of claim 9 as designated in formula IIB.

13. The compound of claim 9 as designated in formula IIC.

14. The compound of claim 9 as designated in formula IID

IID

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F.

5

15. The compound of claim 9 as designated in formula IIE

IIE

wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl, O— $(C_1-C_4)$  alkyl, S— $(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form C=O.

## 15 16. A compound of formula III

Ш

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

5 B is

 $C(=O)R_1$ ,

 $C(=S)R_1$ ,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

D is N when E is C and F is CH when "-----" is a bond, or D is CH when E is N and F is CH<sub>2</sub> when "-----" is absent;

15

10

≀ั V∹w<sup>™</sup> ⟨het∫

is 5-membered heterocyclo or heteroaryl, wherein

"" indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>, NHCO<sub>2</sub>NR<sub>5</sub>;

25

20

J, K, Q independently are  $CR_2$  or N, with the proviso that when any one of J, K, or Q is N, then the other two are  $CR_2$ ;

X, Y, Z independently are  $C=C-R_5$ , O=C,  $CH_2$ ,

CHR<sub>3</sub>, CHR<sub>4</sub>,  $CR_3R_4$  $CH(OR_5)$ , or 5 CHNR<sub>6</sub>R<sub>7</sub>;  $R_1$  is H,  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, 10 O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1-C_4)$  alkyl, S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  $NH_2$ , 15 NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, R<sub>2</sub> is H, 20 halo,  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4)$ alkyl, O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1$ - $C_4)$  alkyl, 25 S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, NH<sub>2</sub>,  $NH(C_1-C_4)alkyl$ ,  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; 30

R<sub>3</sub> and R<sub>4</sub> independently are halo,

aryl,

(CH<sub>2</sub>)<sub>n</sub>-aryl,

heterocyclo,

(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,

heteroaryl, or

 $(CH_2)_n$ -heteroaryl;

wherein n is 0, 1, 2, or 3; or  $R_6$  and  $R_7$  together can form a 5-7-membered ring containing 1, 2, or 3 heteroatoms which are N or S.

10 17. The compound of claim 16, wherein is as defined in claim 2.

18. The compound of claim 16 as designated in formula IIIA.

15

5

19. The compound of claim 16 as designated in formula IIIB.

IIIB

20 20. The compound of claim 16 as designated in formula IIIC.

```
(C_1-C_8)alkyl,
                                              (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                              O—(C_1-C_4)alkyl,
                                              O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
 5
                                              S—(C_1-C_4) alkyl,
                                              S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                              NH_2,
                                              NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,
                                              N((C_1-C_4)alkyl)_2,
                                              NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;
10
                                              aryl,
                                              (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                              heterocyclo,
                                              (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
15
                                               heteroaryl, or
                                               (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                  wherein n is 0, 1, 2, or 3;
                                  R<sub>5</sub> is H,
                                               (C_1-C_8)alkyl,
20
                                              (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                               aryl,
                                               (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                               heterocyclo,
25
                                               (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
                                               heteroaryl, or
                                               (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                  wherein n is 0, 1, 2, or 3;
30
                                  R<sub>6</sub> and R<sub>7</sub> independently are H,
                                               (C<sub>1</sub>-C<sub>8</sub>)alkyl,
                                               (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
```

21. The compound of claim 16 as designated in formula IIID

wherein Ja is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F.

22. The compound of claim 16 as designated in formula IIIE

10

15

5

wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1\text{-}C_8)$ alkyl,  $(C_3\text{-}C_6)$ cycloalkyl, O— $(C_1\text{-}C_4)$  alkyl, S— $(C_1\text{-}C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form C=O.

23. A compound of formula IV:

or a pharmaceutically acceptable salt thereof wherein:

5 A is O,
NH, or
S;

20

25

B is  $C(=O)R_{1},$   $C(=S)R_{1},$  heterocylco, heteroaryl, C(=O)-heterocyclo, or 15 C(=O)-heteroaryl;

D is N when E is C and F is CH when "-----" is a bond, or D is CH when E is N and F is CH<sub>2</sub> when "-----" is absent;

is 5-membered heterocyclo or heteroaryl, wherein "ow" indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-

 $C_4) alkyl, C(=O)R_{1,}OR_5, OC(=O)R_1, NR_6R_7, NHR_5, N(C=O)R_5, \\ NH(C=O)OR_5, NHSO_2R_5, NHSO_2NR_5;$ 

J, K, Q independently are  $CR_2$  or N, with the proviso that when any one of J, K, or Q is N, then the other two are  $CR_2$ ;

X, Y, Z independently are C=C-R<sub>5</sub>, O=C,

CH<sub>2</sub>,

CHR<sub>3</sub>,

10 CHR<sub>4</sub>,

5

CR<sub>3</sub>R<sub>4</sub>,

CH(OR<sub>5</sub>), or

CHNR<sub>6</sub>R<sub>7</sub>;

 $R_1$  is H,

 $(C_1-C_8)$ alkyl,

(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

O— $(C_1$ - $C_4$ )alkyl,

O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

S— $(C_1-C_4)$  alkyl,

S— $(C_3$ - $C_6)$ cycloalkyl,

 $NH_2$ ,

NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,

 $N((C_1-C_4)alkyl)_2$ , or

NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

R<sub>2</sub> is H,

halo,

 $(C_1-C_8)$ alkyl,

 $(C_3-C_6)$ cycloalkyl,

O— $(C_1$ - $C_4$ )alkyl,

O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

S— $(C_1-C_4)$  alkyl, S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  $NH_2$ ,  $NH(C_1-C_4)alkyl$ , 5  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; R<sub>3</sub> and R<sub>4</sub> independently are halo,  $(C_1-C_8)$ alkyl, 10 (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1$ - $C_4)$  alkyl, S—( $C_3$ - $C_6$ )cycloalkyl, 15  $NH_2$ ,  $NH(C_1-C_4)alkyl$ ,  $N((C_1-C_4)alkyl)_2$ , NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; aryl, 20 (CH<sub>2</sub>)<sub>n</sub>-aryl, heterocyclo, (CH<sub>2</sub>)<sub>n</sub>-heterocyclo, heteroaryl, or (CH<sub>2</sub>)<sub>n</sub>-heteroaryl; 25 wherein n is 0, 1, 2, or 3; R<sub>5</sub> is H,  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 30 aryl, (CH<sub>2</sub>)<sub>n</sub>-aryl, heterocyclo,

(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,

heteroaryl, or

(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;

wherein n is 0, 1, 2, or 3;

5

R<sub>6</sub> and R<sub>7</sub> independently are H,

 $(C_1-C_8)$ alkyl,

(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

aryl,

10

 $(CH_2)_n$ -aryl,

heterocyclo,

(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,

heteroaryl, or

(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;

15

wherein n is 0, 1, 2, or 3; or

 $R_6$  and  $R_7$  together can form a 5-7-membered ring containing 1, 2, or 3 heteroatoms which are N or S.

24. The compound of claim 23, wherein

V=W-

is as defined in claim 2.

20

25. The compound of claim 23 as designated in formula IVA.

**IVA** 

25 26. The compound of claim 23 as designated in formula IVB.

27. The compound of claim 23 as designated in formula IVC.

5

The compound of claim 23 as designated in formula IVD 28.

10

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F. Specific calues for K and Q are CH, and CH, respectively.

29.

The compound of claim 23 as designated in formula IVE

wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl, O— $(C_1-C_4)$  alkyl, S— $(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form C=O.

## 30. A compound of formula V:

10

15

or a pharmaceutically acceptable salt thereof wherein:

C(=O)-heterocyclo, or

A is O,
NH, or
S;

B is  $C(=O)R_1,$ 

 $\label{eq:condition} \begin{array}{c} \text{C}(=S)R_1,\\\\ \text{heterocylco},\\\\ \text{heteroaryl}, \end{array}$ 

#### C(=O)-heteteroaryl;

D is N when E is C and F is CH when "-----" is a bond, or D is CH when E is N and F is CH<sub>2</sub> when "-----" is absent;

5

is 5-membered heterocyclo or heteroaryl, wherein "indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>, NHC(=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>;

15

10

J, K, Q independently are  $CR_2$  or N, with the proviso that when any one of J, K, or Q is N, then the other two are  $CR_2$ ;

X, Y, Z independently are  $C=C-R_5$ , O=C,

20

 $CH_2$ ,

CHR<sub>3</sub>,

CHR<sub>4</sub>,

CR<sub>3</sub>R<sub>4</sub>

CH(OR<sub>5</sub>), or

25

 $CHNR_6R_7$ ;

R<sub>1</sub> is H,

 $(C_1-C_8)$ alkyl,

(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

30

O— $(C_1$ - $C_4$ )alkyl,

O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1$ - $C_4)$  alkyl, S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  $NH_2$ , 5 NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  $N((C_1-C_4)alkyl)_2$ , or NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, R<sub>2</sub> is H, 10 halo,  $(C_1-C_8)$ alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O— $(C_1$ - $C_4$ )alkyl, O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1$ - $C_4)$  alkyl, 15 S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  $NH_2$ ,  $NH(C_1-C_4)alkyl,$  $N((C_1-C_4)alkyl)_2$ , or 20 NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl; R<sub>3</sub> and R<sub>4</sub> independently are halo, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 25 O— $(C_1$ - $C_4$ )alkyl, O-(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S— $(C_1-C_4)$  alkyl, S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  $NH_2$ , 30 NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  $N((C_1-C_4)alkyl)_2$ , NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

```
aryl,
                                           (CH_2)_n-aryl,
                                          heterocyclo,
                                           (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
 5
                                           heteroaryl, or
                                           (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                           wherein n is 0, 1, 2, or 3;
                               R<sub>5</sub> is H,
10
                                           (C_1-C_8)alkyl,
                                           (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                           aryl,
                                           (CH<sub>2</sub>)<sub>n</sub>-aryl,
                                           heterocyclo,
15
                                           (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
                                           heteroaryl, or
                                           (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                           wherein n is 0, 1, 2, or 3;
20
                                R<sub>6</sub> and R<sub>7</sub> independently are H,
                                           (C_1-C_8)alkyl,
                                           (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
                                           aryl,
                                           (CH<sub>2</sub>)<sub>n</sub>-aryl,
25
                                           heterocyclo,
                                           (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,
                                           heteroaryl, or
                                           (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;
                                           wherein n is 0, 1, 2, or 3; or
30
                    R<sub>6</sub> and R<sub>7</sub> together can form a 5-7-membered ring containing 1, 2, or 3
         heteroatoms which are N or S.
```

- 31. The compound of claim 30, wherein is as defined in claim 2.
- 32. The compound of claim 30 as designated in formula VA.

33. The compound of claim 30 as designated in formula VB.

5

10

34. The compound of claim 30 as designated in formula VC.

15 35. The compound of claim 30 as designated in formula VD

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F.

5 36. The compound of claim 30 as designated in formula VE

wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl, O— $(C_1-C_4)$  alkyl, S— $(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form C=O.

### 37. A compound which is:

- (S)-N-[2-Oxo-3-(1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(3-phenyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-{3-[3-(2-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(2-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-5 diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-(2-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 10 (S)-N-{3-[3-(3-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-(3-Methroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 15 (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{2-Oxo-3-[3-(3-trifluormethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-20 benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-(3-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 25 (S)-N-{3-[3-(4-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-(4-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-30 benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-

(S)-N-{3-[3-(4-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-[2-Oxo-3-(3-thiophen-3-yl-1,4,5,6-tetrahydro-1,2-diazabenzo[e] azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-{3-[3-(4-Hydroxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{3-[3-(4-Methoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{3-[3-(4-Fluoro-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(5-Hydroxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-{3-[3-(5-Methoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(5-Fluoro-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-[3-(3-Furan-3-yl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-30 2-oxo-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-{3-[3-(4-Hydroxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{3-[3-(4-Methoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Fluoro-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{3-[3-(5-Hydroxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(5-Methoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - $(S)-N-\{3-[3-(5-Fluoro-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e] azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl\}-acetamide;$
  - (S)-N-[2-Oxo-3-(3-pyridin-4-yl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

- (S)-N-{3-[3-(3-Hydroxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-20 benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(3-Methoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-pyridin-4-yl)-1,4,5,6-tetrahydro-
  - (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 30 (S)-N-{3-[3-(3-Fluoro-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(2-Hydroxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(2-Methoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 45 (S)-N-{3-[3-(2-Fluoro-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-[3-(5,6-Dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(3-phenyl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-{3-[3-(2-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{3-[3-(2-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-20 benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- $(S)-N-\{3-[3-(3-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl\}-acetamide;$
- 25 (S)-N-{3-[3-(3-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-30 aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(3-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(4-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[4-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(4-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-[2-Oxo-3-(3-thiophen-3-yl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

30

- (S)-N-{3-[3-(4-Hydroxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Methoxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-thiophen-3-yl)-5,6-dihydro-4H-1-20 oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(4-Fluoro-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(5-Hydroxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(5-Methoxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-thiophen-3-yl)-5,6-dihydro-4H-1oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{3-[3-(5-Fluoro-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-[3-(3-Furan-3-yl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-{3-[3-(4-Hydroxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(4-Methoxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-azabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 5 (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-furan-3-yl)-5,6-dihydro-4H-1oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; 10 (S)-N-{3-[3-(4-Fluoro-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-azabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-(5-Hydroxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-15 benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-(5-Methoxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-azabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 20 (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-furan-3-yl)-5,6-dihydro-4H-1oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; 25 (S)-N-{3-[3-(5-Fluoro-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-azabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-[2-Oxo-3-(3-pyridin-4-yl-5,6-dihydro-4H-1-oxa-2-aza-30 benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide; (S)-N-{3-[3-(3-Hydroxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-azabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 35 (S)-N-{3-[3-(3-Methoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-azabenzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-pyridin-4-yl)-5,6-dihydro-4H-1oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide; 40 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-pyridin-4-yl)-5,6-dihydro-4H-1oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(3-Fluoro-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-

benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{3-[3-(2-Hydroxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Methoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(2-Fluoro-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

30

45

(S)-N-[2-Oxo-3-(1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide;

- (S)-N-[2-Oxo-3-(3-phenyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-20 yl)-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-{3-[3-(2-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(2-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(3-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{3-[3-(3-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;

- $(S)-N-\{3-[3-(3-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e] azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl\}-acetamide;$
- 5 (S)-N-{3-[3-(4-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

25

40

(S)-N-{3-[3-(4-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diazabenzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(4-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-[3-(5,6-Dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-[2-Oxo-3-(3-phenyl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-{3-[3-(2-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-30 benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(2-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(3-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(3-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{3-[3-(4-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(4-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
  - (S)-N-{3-[3-(4-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-[3-(2-Methyl-9,10-dihydro-4H-3-thia-1-aza-benzo[f]azulen-7-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-[3-(2-Methyl-9,10-dihydro-4H-3-thia-1-aza-benzo[f]azulen-6-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-[3-(2-Methyl-5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5ylmethyl] acetamide;
- (S)-N-[3-(2-Amino-5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-8-yl)-2-35 oxo-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-[3-(2-Methyl-3,4,5,6-tetrahydro-1,3-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- 40 (S)-N-[2-Oxo-3-(2-trifluoromethyl-3,4,5,6-tetrahydro-1,3-diazabenzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
  - (S)-N-[2-Oxo-3-(3,4,5,6-tetrahydro-2,3-diaza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide; or

- (S)-N-[3-(5,6-Dihydro-4H-3-oxa-2-aza-benzo[e] azulen-9-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide.
- 38. A pharmaceutical formulation comprising a compound of claim 1 admixed
  5 with a pharmaceutically acceptable diluent, carrier, or excipient.
  - 39. A method of treating a bacterial infection in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.